Ignite Creation Date:
2025-12-24 @ 3:59 PM
Ignite Modification Date:
2025-12-25 @ 3:51 PM
Study NCT ID:
NCT00102466
Status:
COMPLETED
Last Update Posted:
2020-12-17
First Post:
2005-01-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes
Sponsor:
Novartis Pharmaceuticals
Organization:
Study Overview
Official Title:
Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is not being conducted in the United States. Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to that of gliclazide in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: